scholarly journals Pharmacological inhibition of nonsense-mediated RNA decay augments HLA class I-mediated presentation of neoepitopes in MSI CRC

2020 ◽  
Author(s):  
Jonas P. Becker ◽  
Dominic Helm ◽  
Mandy Rettel ◽  
Frank Stein ◽  
Alejandro Hernandez-Sanchez ◽  
...  

AbstractMicrosatellite-unstable (MSI) colorectal cancer is characterized by the accumulation of somatic insertion/deletion (InDel) mutations potentially generating tumor-specific, frameshifted protein sequences. Such mutations typically generate premature translation termination codons targeting the affected mRNAs to degradation by nonsense-mediated RNA decay (NMD), limiting the synthesis and HLA class I-mediated presentation of tumor-specific InDel neoepitopes. We reasoned that the NMD inhibitor 5-azacytidine (5AZA) could serve to increase the expression of NMD-sensitive neoepitopes and analyzed the immunopeptidome of MSI HCT-116 cells using a proteogenomic approach. After immunoprecipitation of HLA:peptide complexes, we identified more than 10,000 HLA class I-presented peptides by LC-MS/MS including five InDel neoepitopes. The InDel neoepitopes were verified on the genomic, transcriptomic, and peptidomic level. Treatment with 5AZA increased the expression of the corresponding frameshift- and premature termination codon-bearing mRNAs and enhanced the presentation of peptides originating from known NMD targets and one of the identified InDel neoepitopes. By analyzing an array of MSI colorectal cancer cell lines and patient samples, we found the underlying frameshift mutation to be highly recurrent and immunization with the corresponding neoepitope induced strong CD8+ T cell responses in an HLA-A*02:01 transgenic mouse model. Our data directly show that peptides originating from frameshifted open reading frames due to InDel mutations in mismatch repair-deficient cells are presented on the cell surface via HLA class I. Moreover, we demonstrate the utility of NMD inhibitor-enhanced HLA class I-mediated presentation of InDel neoepitopes as well as their immunogenicity, uncovering the clinical potential of NMD inhibition in anti-cancer immunotherapy strategies.One Sentence SummaryImmunopeptidomics identified increased HLA class I-mediated presentation of immunogenic, frameshift-derived neoepitopes following NMD inhibition.

2020 ◽  
Author(s):  
Arfon G M T Powell ◽  
Colin Richards ◽  
Jonathan J Platt ◽  
Clare Orange ◽  
Lindsay Bennett ◽  
...  

AbstractPurposeThe host inflammatory response is an important determinant of cancer outcome, however, the factor/s that regulate this response remains unclear. We aimed to determine if Human Leukocyte Antigen (HLA) class I and tumour cell proliferation are associated with CD8+ infiltration and survival in patients undergoing potentially curative resection for colorectal cancer.MethodsHLA class I expression (W6/32 and B2-microglobulin) and tumour proliferation index (Ki67) were quantified using immunohistochemistry on tissue micro arrays (TMA). The local inflammatory response at the invasive margin was assessed using the Klintrup-Makinen (K-M) score and CD8+ infiltration was assessed at the invasive margin (mCD8+), stroma (sCD8+) and cancer cell nests (cCD8+).ResultsPreserved HLA class I expression was associated with lower Dukes’ stage (p=0.032), lower T stage (p=0.040) and higher cCD8+ (p=0.003). High Ki67 was associated with a good K-M score (p<0.001), higher mCD8+ (p=0.033), higher sCD8+ (p=0.025) and higher cCD8+ (p<0.001). On binary logistical regression analysis both preserved HLA class I expression (HR 1.99 95%CI (1.13–3.51),p=0.012) and high Ki67 (HR 2.63 95%CI (1.08–6.38),p=0.033) were independently associated with higher CD8+ infiltration within the cancer cell nests. On multivariate survival analysis, preserved HLA class I expression was associated with disease free (HR 0.47 95%CI (0.25–0.89),p=0.020) and cancer specific survival (HR 0.52 95%CI (0.28–0.97),p=0.038).ConclusionThis study suggests that a pronounced local inflammatory response is independently associated with both, HLA class I expression and tumour proliferation.


JCI Insight ◽  
2021 ◽  
Author(s):  
Tomomi Hirama ◽  
Serina Tokita ◽  
Munehide Nakatsugawa ◽  
Kenji Murata ◽  
Yasuhito Nannya ◽  
...  

Author(s):  
Fanny Ledys ◽  
Quentin Klopfenstein ◽  
Caroline Truntzer ◽  
Laurent Arnould ◽  
Julie Vincent ◽  
...  

1992 ◽  
Vol 51 (3) ◽  
pp. 379-385 ◽  
Author(s):  
Loukas Kaklamanis ◽  
Kevin C. Gatter ◽  
Ann B. Hill ◽  
Neil Mortensen ◽  
Adrian L. Harris ◽  
...  

2021 ◽  
Author(s):  
Yuriko Minegishi ◽  
Kazuma Kiyotani ◽  
Kensaku Nemoto ◽  
Yoshikage Inoue ◽  
Yoshimi Haga ◽  
...  

Knowing the nature of human leukocyte antigen (HLA) peptides, also called as immunopeptides, is indispensable to realize the cancer precision medicine such as cancer vaccination and the better prediction of efficacy for immunocheckpoint inhibitor (ICI) treatment. Direct interrogation of immunopeptides by mass spectrometry (MS) is of great use for that purpose but the reality in analyses of scarce tissue samples still confronts technical challenges. To elucidate characteristics of HLA class-I immunopeptides specifically presented on colorectal cancer (CRC), the optimized immunopeptide isolation method and differential ion mobility mass spectrometry (DIM-MS) with whole exome sequencing (WES)-based personalized database were established and subjected to differential analysis of tumor or normal tissues of CRC patients. From pilot experiments using 108 cells of colon cancer cell line HCT116, total 9,249 unique immunopeptides, including total 11 neoantigens, were identified. Next, approximately 40 mg of tumor or normal regions of CRC tissues were collected from 17 patients and analyzed by our personalized immunopeptidomic technology. As the result, 44,785 unique immunopeptides were profiled, in which 2 neoantigens carrying the mutation KRAS-G12V or CPPED1-R228Q were identified. Interestingly, specific amino acid usage of C-terminus trimming of immunopeptides was found in tumor-exclusive immunopeptides. Thus, our personalized immunopeptidome analysis significantly expands presented antigen knowledgebase and allows direct determination of neoantigens from scarce tissue specimens. This advanced immunopeptidomics holds promise to new outlook of research in immunopeptides both from basic and clinical aspects.


Sign in / Sign up

Export Citation Format

Share Document